# Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth

> **NCT00659022** · PHASE2 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Liver Neoplasms

## Interventions

- **PROCEDURE:** immediate surgery (resection of primary colorectal tumor)
- **DRUG:** neo-adjuvant treatment with bevacizumab
- **DRUG:** neoadjuvant treatment with capecitabine and oxaliplatin
- **DRUG:** neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin

## Key facts

- **NCT ID:** NCT00659022
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659022, "Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00659022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*